폐암 (NSCLC) | 바이오정보모아

AntibodystaleMerck Sharp & Dohme LLCPhase 3

H2 receptor antagonist (H2 receptor antagonist)

Ovarian Cancer; Fallopian Tube Cancer · Lung Neoplasm Malignant

#LungNeoplasmMalignant#Antibody#Phase3#항체#면역항체+4

임상시험 31상태 RECRUITING

ADCBiologicstaleAstraZenecaPhase 2

Vistusertib (Vistusertib)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

효능 ORR 9.5%임상시험 30상태 RECRUITING

ADCBiologicstaleDaiichi SankyoPhase 3

DS-1062a (DS-1062a)

Non-small Cell Lung Cancer · Metastatic Lung Cancer

#MetastaticLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 74%임상시험 28상태 ACTIVE

AntibodystaleAstraZenecaPhase 2

Oleclumab (Oleclumab)

Non-small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3

효능 ORR 56.5%임상시험 28상태 RECRUITING

ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

Patritumab Deruxtecan (Patritumab Deruxtecan)

Lung Neoplasm Malignant · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 56%임상시험 28상태 RECRUITING

ADCBiologicstaleEMD Serono Research & Developme…Phase 2

Tepotinib (Tepotinib)

Non-small Cell Lung Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 54.7%임상시험 28상태 ACTIVE

ADCBiologicstaleBristol-Myers SquibbPhase 3

Amrubicin (Amrubicin)

Lung Cancer · Small Cell Lung Cancer

#SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 80%임상시험 25상태 RECRUITING

ADCBiologicstaleAstraZenecaPhase 2

AZD2936 (AZD2936)

Advanced or Metastatic NSCLC · Advanced or Metastatic NSCLC

#AdvancedorMetastaticNSCLC#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 24상태 RECRUITING

ADCBiologicstaleDaiichi SankyoPhase 1

FL-DP (HER3-DXd, HER3-DXd (FL-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 56%임상시험 24상태 RECRUITING

AntibodystaleImmunityBio, Inc.Phase 2

Necitumumab (Necitumumab)

Squamous Cell Carcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3

효능 ORR 76%임상시험 23상태 DISCONTINUED

AntibodystalePfizerPhase 1

sasanlimab (sasanlimab)

Carcinoma, Pancreatic Ductal; Colorectal Neoplasms · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase1#항체#면역항체+5

효능 ORR 33.3%임상시험 23상태 DISCONTINUED

ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

HER3-DXd (HER3-DXd)

Carcinoma, Non-Small-Cell Lung · HER3

#HER3#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

효능 ORR 56%임상시험 22상태 RECRUITING

ADCBiologicstaleAstraZenecaPhase 1

MEDI5752 (MEDI5752)

Advanced or Metastatic NSCLC · Advanced or Metastatic NSCLC

#AdvancedorMetastaticNSCLC#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1

임상시험 22상태 RECRUITING

AntibodystaleAstraZenecaPhase 2

Monalizumab (Monalizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2

효능 ORR 23.9%임상시험 22상태 RECRUITING

CGTBiologicstaleShanghai Yunying Medical Techno…Phase 1

R130 (Recombinant oncolytic herpes simplex virus type 1, Recombinant oncolytic herpes simplex virus type 1 (R130))

Lung Cancer; Bronchial Cancer · Sarcoma

#Sarcoma#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 21상태 ACTIVE

AntibodystaleJanssen Research & Development,…Phase 2

Cetrelimab (Cetrelimab)

Carcinoma, Non-Small-Cell Lung · Neoplasms

#Neoplasms#Antibody#Phase2#항체#면역항체+4

효능 ORR 75%임상시험 20상태 RECRUITING

ADCBiologicstaleBioNTech SEPhase 3

Pumitamig (Pumitamig)

Non-small Cell Lung Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2

임상시험 19상태 RECRUITING

CGTBiologicstaleChongqing Precision Biotech Co.…Phase 1

Targeted CEA CAR-T (Targeted CEA CAR-T)

Advanced Lung Cancer · CEA

#CEA#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 19상태 RECRUITING

AntibodystaleMerck Sharp & Dohme LLCPhase 2

Vibostolimab (Vibostolimab)

Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#항체#면역항체+3

효능 ORR 71.7%임상시험 19상태 RECRUITING

ADCBiologicstaleAstraZenecaPhase 3

Volrustomig (Volrustomig)

Metastatic Non-small Cell Lung Cancer · Endometrial Cancer

#EndometrialCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2

임상시험 19상태 RECRUITING

4 / 15 페이지

← 이전 다음 →

갱신 기록 없음 · 14일 주기 · 방문 47 / 5,173